<p>Surgical robotics has been hospital-bound since the Da Vinci system introduced robot-assisted laparoscopy in the late 1990s. The capital cost ($1.5-2.5M per system), technical complexity, and space requirements confined these systems to large hospital surgery centers. That is changing, driven by a new generation of smaller, less expensive, and easier-to-operate systems.</p>
<h2>The New Systems</h2>
<p>Medtronic's Hugo system and CMR Surgical's Versius are both designed for ambulatory surgery centers (ASCs) — smaller facilities that handle same-day procedures. Both systems cost under $1M, require less floor space than Da Vinci, and have reduced setup times that make them economical at lower procedure volumes. They target orthopedic, gynecological, and urological procedures — the highest-volume surgical categories in outpatient settings.</p>
<p>Stryker's Mako robotic arm, already in use for joint replacements, is being marketed to orthopedic practices rather than only hospitals. A knee replacement clinic that performs 10-15 procedures per week can now justify the capital cost when amortized over several years.</p>
<h2>Clinical Implications</h2>
<p>Outpatient surgery is already growing independent of robotics: better anesthesia, better pain management, and payer pressure to move procedures out of expensive hospital settings have pushed 60%+ of eligible procedures to ASCs in the US. Robot-assisted techniques reduce incision size and trauma, which reduces recovery time — directly enabling outpatient settings for procedures that previously required hospital stays.</p>
<h2>Access and Equity</h2>
<p>The geographic distribution of robotic surgery has historically correlated with income and hospital system resources. Outpatient systems at lower price points may improve access, but the capital cost remains significant for independent or rural practices. Leasing and procedure-based pricing models (paying per use rather than per system) are being explored to lower the barrier further.</p>